Pipeline

BEAM Alliance

The pipeline of antimicrobial products under development is thin. But innovative.

Indeed, the antimicrobial products under development display a variety of pharmacological effects and applications.

They are described in the BEAM Infection Curve (BIC); read the memo to find out more.

Take a look at all these products that could save lives in the future.

BEAM Alliance

Pipeline RX

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
Ilya PharmaILP101-InhaleOtherMDR bacteria in the mucus layer of lung/upper respiratory tract infections. Restoring lung function in or following ARDS.Pre-clinical
Ilya PharmaILP100-OralOtherTreating colitis, improving mucosal healing, limiting risk of sepsis with MDR bacteria, increasing number of patients that can stay on ICIs, improving PFSIND/CTA ready
Ilya PharmaILP100-TopicalOtherHealing skin wounds in pediatric patients with interferonophaties like SAVI (STING Associated Vasculophaty with onset in infancy)Phase III
Basilea Pharmaceutica InternationalBAL2062 3aNMEInvasive aspergillosis Phase I
Basilea Pharmaceutica InternationalFosmanogepix3aNMEInvasive mold infections (including invasive aspergillosis, fusariosis, Scedoporium and Lomentospora, mucormycosis and other rare mold infections)Phase II
Basilea Pharmaceutica InternationalFosmanogepix3aNMECandidemia / invasive candidiasis (including Candida auris)Phase III
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEAspergillosis, (including invasive aspergillosis and chronic pulmonary aspergillosis),  mucormycosis and cryptococcosisMarketed
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEInvasive aspergillosis and mucormycosis Marketed
Eligo BioscienceEB0034aPhageHemolytic uremic syndrome (HUS)IND/CTA ready
OM PharmaUro-Vaxom®1aOtherRecurrent lower urinary tract infections (i.e. cystitis)Marketed
OM PharmaBroncho-Vaxom® (Bacterial Lysates – OM-85)1aOtherRecurrent Respiratory Tract Infections (RTIs)Marketed
OM PharmaOM-851aOtherRespiratory Tract Infections (RTIs)Phase II
OM PharmaOM-891aOtherCommunity acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Phase I
OM PharmaOM-851aOtherUncomplicated urinary tract infections (uUTI)Phase I
DevsHealthMulti-resistant s. aureus novel treatmentNMES. aureus (methicillin resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
ArrePathAP-0013aNMEE. coli, K. pneumoniae, Enterobacter spp., Citrobacter spp., Other Enterobacterales, Salmonella spp., Shigella spp., E. faecium, N. gonorrhoeae, H. influenzae / Complicated urinary tract infections (cUTI)Lead opt
Tabrixanti-virulence agents3aNMEMycobacterium tuberculosis / Cystic fibrosis associated infectionsIND/CTA ready
GranulyticsUndisclosed3aProtein/PeptideE. coli, S. aureusPre-clinical
Santero TherapeuticsSAN-Sa13aNMES. aureusPre-clinical
UltupharmaULT13aNMEE. faecium, S. aureus, S. pneumoniae, Group A Streptococci / Complicated urinary tract infections (cUTI)IND/CTA ready
UltupharmaULT2C3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., S. aureus, S. pneumoniae, H. influenzae, Group A Streptococci /Skin and Skin-structure infections (ABSSSI)IND/CTA ready
UltupharmaULT2B3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT2A3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., S. aureus, H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT33aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Other Enterobacterales, P. aeruginosa / Skin and Skin-structure infections (ABSSSI)IND/CTA ready
VAXDYNAcinetoVax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNEcoVax1aVaccineA. baumannii, E. coli / Bloodstream infectionsPre-clinical
VAXDYNP-Vax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNK-Vax1aVaccineA. baumannii, K. pneumoniae / Bloodstream infectionsIND/CTA ready
Epynext TherapeuticsEPY-0013aAntibodyP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Arivin therapeuticsViri-24253aNMEK. pneumoniae, P. aeruginosa / Chronic open woundsPre-clinical
Arivin therapeuticsViri-013aNMEK. pneumoniae, P. aeruginosa / Cystic fibrosis associated infectionsPre-clinical
Thioredoxin SystemsEbsArgent3aNMEA. baumannii, P. aeruginosa, S. aureus / Complicated urinary tract infections (cUTI)IND/CTA ready
BioNTech R&DBNT3313aProtein/PeptideBacterial VaginosisIND/CTA ready
Basilea Pharmaceutica InternationalTonabacase 3aNMESevere staphylococcal infections Phase I
Basilea Pharmaceutica InternationalBAL2420 (LptA inhibitor)3aNMESevere Enterobacteriaceae infections Pre-clinical
Nexbiome TherapeuticsBGA-19013aAntibodyH. piloriPre-clinical
Nexbiome TherapeuticsBGY-16013aAntibodyCandida spp and G. vaginalisIND/CTA ready
Nexbiome TherapeuticsNIN-21013aProtein/PeptideEnterococcus faecium, S. aureus / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
SurvivXSUR-1013cNMEImmune-oncology / SepsisIND/CTA ready
Infex TherapeuticsGON-X3aNMEN. Gonorrhoeae / Resistant Neisseria GonorrhoeaLead opt
Infex TherapeuticsVAP-X4aNMEP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
Disperazol PharmaDisperazol3dNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Disperazol PharmaDisperazol1bNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Osta TherapeuticsOsta 27OtherA. baumannii, P. aeruginosa, M. tuberculosis / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
AUROBAC THERAPEUTICSATX4013aProtein/PeptideGram-negative pathogens / Treatment of HAP/VAP caused by Gram-negative bacteria as 1st line therapy suppressing AMR emergencePre-clinical
AUROBAC THERAPEUTICSATX1014aNMETreatment of early septic shock to prevent progression and improve outcomePre-clinical
NanoRevivStaph-EX3aOtherS. aureus, Group A Streptococci, Group B Streptococci / Skeletal InfectionsPre-clinical
discoveric bio betaNIDB-30023aNMEP. aeruginosa / Cystic fibrosis associated infectionsLead opt
discoveric bio betaNIDB-30013aNMEE. coli, K. pneumoniae / Bloodstream infectionsLead opt
Omnix MedicalOMN713aProtein/PeptideSalmonella spp., S. aureus / Skin and Skin-structure infections (ABSSSI)Pre-clinical
Omnix MedicalOMN513aProtein/PeptideEnterobacter spp., P. aeruginosa, S. aureus / Cystic Fibrosis associated infectionsPre-clinical
XF-731bNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositisPre-clinical
XF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / BurnsPre-clinical
XF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitisPre-clinical
XF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infectionsPre-clinical
XF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infectionPhase II
NTCD-M31bNMEToxigenic strains of C. difficile / Prevention of recurrence of C diff infectionPhase II
SPOR-COV1aNMERespiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infectionsPre-clinical
Infex TherapeuticsRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase II
Infex TherapeuticsMET-X3dNMEA. baumannii, P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)IND/CTA ready
Infex TherapeuticsRDX-023aNMEGram-negative AMR infectionsLead opt
AdjuTec PharmaAPC2473dNMEE. coli, K. pneumoniae / Complicated urinary tract infections (cUTI)IND/CTA ready
F2GOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractoryPhase III
AdjuTec PharmaAPC1483dNMEK. pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI)Phase I
OLGRAMOL20015aProtein/PeptideP. aeruginosa; Broad-spectrum G+/G- / Cystic fibrosis associated infectionsPre-clinical
Selmodslm 5003aNMEE. coli; Broad-spectrum G+/G- / Complicated urinary tract infections (cUTI)IND/CTA ready
Selmodslm 3003aNMEK. pneumoniae; Broad-spectrum G+/G- / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Selmodslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris / Invasive spergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisaLead opt
Assuré MedicalSol-UTI1bOtherP. aeruginosa, S.aureus / Uncomplicated urinary tract infections (uUTI)Pre-clinical
BioVersysBV1003aNMEA. baumannii / HAP, VAP, BSIPhase II
ANTABIOSBLi (ANT3310)3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) IND/CTA ready
VibioSphenVIKYNG3aOtherA. baumannii, P. aeruginosa, S. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
QureTech BioGmP3aNMEE. faecium, S. aureus / Skin and Skin-structure infections (ABSSSI)Lead opt
QureTech BioMTI3aNMEMycobacterium tuberculosis / TuberculosisLead opt
Omnix MedicalOMN63a/5aProtein/PeptideA. baumannii, P. aeruginosa, E. coli, K. pneumoniae; Enterobacter spp / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase I
Northern AntibioticsNAB8153aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
Northern AntibioticsNAB7393aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
tamrisa2G-DAB3aNMEEnterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI)Lead opt
tamrisaEBL-14633aNMEEnterobacterales/Complicated urinary tract infections (cUTI)Pre-clinical
IMMUNETHEPUNImAb3cAntibodyE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
IMMUNETHEPPNV1aVaccineE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci /Healthcare associated CAPIND/CTA ready
HypharmHY-1331bPhageStaphylococcus aureus/Nasal colonization with MRSAPhase I
Eligo BioscienceEB0041bPhageEscherichia coli; Klebsiella pneumoniae/Bloodstream infectionsPre-clinical
Debiopharm InternationalDebio 14533aNMENeisseria gonorrhoeae / GonorrhoeaIND/CTA ready
Debiopharm InternationalAfabicin3aNMEStaphylococcus spp./ABSSSI (caused by S. aureus), bone and joint infectionsPhase II
CombioxinCAL024aOtherVirulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumoniaPhase II
Centauri TherapeuticsABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPre-clinical
Centauri TherapeuticsABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersysBV2004aNMES. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersysBV5003aNMEA. baumannii, S. aureus, Mycobacterium tuberculosis / Cystic fibrosis associated infectionsLead opt
BioVersysalpibectir (BVL-GSK098)3dNMEM. tuberculosis/TuberculosisPhase II
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMEHospital- and community-acquired bacterial pneumonia (HABP, CABP)Marketed
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMEStaphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP)Marketed
ANTABIOPEi (ANT3273)3cNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
ANTABIOMBLi (ANT2681)3dNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI)IND/CTA ready
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, APPhase III
AktheliaAKT-0113cNMEE. coli, Salmonella spp / Febrile NeutropeniaPre-clinical
< PreviousPage 1/10show allNext >

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline DX

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
Dermatophyte LFAPathogen IDgenera Trichophyton, Microsporum, Epidermophyton /
Suspected dermatophyte infection of hair, skin or nails 		Other sample type
LFIA
<30 minutes		Prototype in Lab
Ocular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use		Other sample type
LFIA
<30 minutes		Prototype in Lab
Ocular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use		Other sample type
PCR/qPCR
<2h		Feasibility Phase
CocciIDPathogen IDCoccidioides immitis and C. posadasii /
Suspected lung infection in patient who has recently travelled to an endemic area.		From serum/plasma
PCR/qPCR
<2h		Feasibility Phase
HistoIDPathogen IDHistoplasma capsulatum /
Individuals with cellular immunity deficiencies, such as patients with HIV/AIDS infection. Mild respiratory illness in patients who have recently travelled to highly endemic regions		From serum/plasma
PCR/qPCR
<2h		Development Phase
MucorIDPathogen IDMucorales species; to include Rhizopus spp., Mucor spp., Lichtheimia spp., Cunninghamella spp., and Rhizomucor spp. /
Suspected fungal infection in patients predisposed by diabetes mellitus, corticosteroids and immunosuppressive drugs, primary or secondary immunodeficiency, hematological malignancies and hematological stem cell transplantation, solid organ malignancies and solid organ transplantation		From serum/plasma
PCR/qPCR
<2h		Development Phase
MicrobiraMAAP-IRPathogen ID75% of Routine Clinical Isolates
Bacteria 94% correct identification: yeasts 95%		From isolated colony
Infrared spectroscopy
<30 minutes		CE-IVD and/or FDA 510k
MicrobiraMicrobira PrototypeFrom PBS + Isolated colony
Infrared spectroscopy
<4h		Prototype in Lab
MicrobiraMicrobira PrototypeFrom positive blood culture
Infrared spectroscopy
<30 minutes		Prototype in Lab
NosticsDUTIPathogen IDMultiplex bacteria
Urinary Tract infections		From urine
Surface Enhanced Raman Spectroscopy
<30 minutes		Feasibility Phase
MolsidfMicRapid antimicrobial susceptibility testAll
AST		From isolated colony
Proprietary reader
<4h		Feasibility Phase
MolsidPythia UTIAMR Mechanism of Resistance IDAll
From urine
Microplate-reader
<2h		Development Phase
MolsidPythia StaphAMR Mechanism of Resistance IDS. aureus
From isolated colony
Microplate-reader
<2h		Development Phase
< PreviousPage 1/2show allNext >

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

BEAM Alliance ©2025

Legal notice | Photo credits

Connect with us